Immunotherapeutics from the group of PD-1 inhibitors (nivolumab, pembrolizumab), a combination of two-tier immunotherapy of PD-1 and CTLA-4 inhibitors (nivolumab and ipilimumab) and BRAF inhibitors (vemurafenib, dabrafenib)—and MEK (cobimetinib, trametinib) signaling pathways in the case of BRAF V600 mutation—are used as the first line treatment for metastatic melanoma according to ASCO and NCCN guidelines [12]. The gene discussed is PDCD1; the disease is metastatic melanoma.